NVP022 targets the metabolic components of NASH by using mild, liver-targeted protonophores to increase energy expenditure, remove excess fat storage in the liver and thereby counteract the pathophysiological processes in NASH. NVP022 is NeuroVive’s second project for NASH, complementing the direct anti-fibrotic action of the company’s NV556 project.
Mitochondrial protonophores, such as dinitrophenol (DNP) have long been known to promote weight loss and impact markers of NASH in preclinical models. NeuroVive’s innovative compounds in the NVP022 project have been designed to have an overall improved therapeutic index and by specifically targeting these novel compounds to the liver they will ensure good safety and tolerability in treatment of NASH.
“Our project has received great interest, scoring in the top 10 per cent of abstracts. This reflects the high unmet medical need of NASH and interest in finding new treatment approaches of the disease processes. The discovery project NVP022 is based on NeuroVive’s core competence in mitochondrial energy regulation and the partner company Isomerase’s innovative chemistry capabilities, says Eskil Elmér, Chief Scientific Officer and VP of Discovery at NeuroVive.
The abstract "Preclinical analysis of liver-targeted, mild mitochondrial protonophores for treatment of non-alcoholic fatty liver disease and steatohepatitis" has been selected as a Presidential Poster of Distinction for presentation at The Liver Meeting 2017, held in Washington DC, October 20-24, 2017.
About The Liver Meeting
The Liver Meeting provides a forum for the exchange of groundbreaking basic, translational and clinical research in diseases of the liver and biliary tract and in liver transplantation.
Accepted abstracts from The Liver Meeting 2017 is published in the October issue of Hepatology, the official journal of AASLD, https://www.aasld.org/publications/hepatology-0
Poster title: Preclinical analysis of liver-targeted, mild mitochondrial protonophores for treatment of non-alcoholic fatty liver disease and steatohepatitis.
Authors: Magnus Hansson, Steven Moss, Sarah Piel, Imen Chamkha, Alvar Grönberg, Matthew Gregory, Eskil Elmér
Presentation date: October 24, 2017
Time: 12:30-2:00 pm EST
Place: Walter E. Washington Convention Center, Washington DC
For further information, please contact:
Erik Kinnman, CEO NeuroVive, Tel: +46 (0)46 275 62 21 or email@example.com
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
Inflammation and excess fat in the liver are symptoms of Non-Alcoholic SteatoHepatitis (NASH), a condition that causes scarring (fibrosis) of the liver which can lead to cirrhosis of the liver and liver cancer (hepatocellular carcinoma). There is a strong link between NASH and other metabolic disorders, such as diabetes and obesity. The disease is common all over the world and about 3-5% of all Americans (about 15 million people) suffer from NASH. There are currently no registered treatment options available.
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).